Inclusion Criteria:~* Probable Alzheimer disease, based on the National Institute of Neurological and
Communicative Disorders and Stroke (NINCDS)/Alzheimer's Disease and Related Disorders Association (ADRDA) and
Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV-TR) criteria~* Mini-Mental State
Exam (MMSE) score at screening between 13 and 20, inclusive~* Body mass index (BMI) between 18 and 36 kilograms
per square meter (kg/m\^2) (inclusive) at screening~* Modified Hachinski Ischemia Score of less than or equal
to (≤) 4~* Participants with Cornell Scale for Depression in Dementia (CSDD) scores ≤ 13 at screening~*
Receiving treatment with donepezil, rivastigmine, galantamine or any AChEIs in combination with memantine for
at least 4 months before screening, with their dose and formulation stabilized at least 3 months before
screening. All formulation and dosages are allowed except donezepil 23 mg (alone or in combination)~* Females
of childbearing potential must have a negative pregnancy test and must agree to use effective contraception~*
Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane)~* Have a reliable caregiver or some
other identified responsible person who has frequent contact with the participant~
